YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
QuidelOrtho (QDEL) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurrin…
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.07 per share a year ago. These figures are adjusted for non-recurring items.…
SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today anno…
SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today anno…
CeriBell, Inc. (NASDAQ:CBLL) is among the Best Brain-Computer Interface Stocks. On June 8, CeriBell, Inc. (NASDAQ:CBLL) reported a study published in Critical Care Medicine that higher AI-detected seizure burden is linked with increased od…
CeriBell logo Key Points Interested in CeriBell, Inc.? Here are five stocks we like better. CeriBell posted strong Q1 growth, with revenue rising 29% year over year to $26.5 million, driven by record headband utilization and the company’s…
Green Thumb Industries Inc. (GTBIF) shares soared 10% in the last trading session to close at $7.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 9.8% gain o…
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned 3.70% (gross) an…
CeriBell logo Key Points $89 million revenue in 2025 with 36% YoY growth and 88% gross margins, plus $159 million cash and 31 consecutive quarters of sequential growth — yet only ~3% penetration (647 of ~6,000 U.S. hospitals), signaling su…
CeriBell logo Key Points Management reiterated 2026 top-line growth guidance of 25%–29%, citing a larger salesforce (territories up from ~35 to ~55), a footprint in about 11% of U.S. hospitals and roughly 30% in‑account penetration as cata…
CeriBell, Inc. (NASDAQ:CBLL) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.Cautious Guidance Offsets Solid Q4 for CeriBell, Inc. (CBLL), Says Canaccord CeriBell, Inc. (NASDAQ:CBLL) secures the twelfth pl…
(RTTNews) - CeriBell, Inc. (CBLL), a commercial-stage medical technology company, reported an increase in revenue for the fourth quarter and full year of 2025, and also provided revenue guidance for full-year 2026. For the fourth quarter o…
CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring items. This…
CeriBell, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Market Expansion Achieved 36% annual revenue growth driven by disciplined execution and the predictable, recurring nature of the point-of-care EEG business model…
Image source: The Motley Fool. DATE Tuesday, February 24, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer & Co-Founder — Xingjuan Chao Chief Financial Officer — Scott Blumberg VP, Investor Relations — Brian Johnston Full Con…
This article first appeared on GuruFocus. Exploring the Fourth Quarter 2025 13F Filing Chuck Royce (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing insights into his investment moves during th…
VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]. This systemic re-rating is driven by he…
CeriBell Inc. CBLL recently announced that the FDA has granted Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution designed for use in hospital settings. The designation highlights…
Ceribell SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, t…
CeriBell Inc. CBLL recently announced that the FDA has given 510(k) clearance for its latest delirium monitoring solution, making it the one and only FDA-cleared solution for continuous tracking of delirium. This milestone confirms the Cer…
Issued on behalf of Aleen Inc. VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Last month marked a major turning point as Google launched Gemini 3[1], proving that new AI models can now outpe…
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today anno…
SUNNYVALE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today anno…
Image source: The Motley Fool. Date Tuesday, November 4, 2025 at 4:30 p.m. ET Call participants Chief Executive Officer — Xingjuan ChaoChief Financial Officer — Scott Blumberg Need a quote from a Motley Fool analyst? Email pr@fool.com Take…
Earnings Call Insights: CeriBell, Inc. (CBLL) Q3 2025 MANAGEMENT VIEW * CEO Xingjuan Chao reported continued execution on growth initiatives and described CeriBell as the “category leader in the point-of-care EEG.” Chao highlighted a 31% y…
* CeriBell press release [https://seekingalpha.com/pr/20293154-ceribell-reports-third-quarter-2025-financial-results] (CBLL [https://seekingalpha.com/symbol/CBLL]): Q3 GAAP EPS of $0.37. * Revenue of $22.6M. MORE ON CERIBELL * Seeking Alph…
SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repo…
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today anno…
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological cond…
CeriBell, Inc. (NASDAQ:CBLL) is one of the best medical device stocks to buy according to analysts. J.P. Morgan analyst Robbie Marcus maintained a Buy rating on CeriBell, Inc. (NASDAQ:CBLL) on August 5, setting a price target of $21.00.5 F…
* CeriBell press release [https://seekingalpha.com/pr/20190071-ceribell-reports-second-quarter-2025-financial-results] (NASDAQ:CBLL [https://seekingalpha.com/symbol/CBLL]): Q2 GAAP EPS of -$0.38 beats by $0.02. * Revenue of $21.2M (+38% Y/…
Earnings Call Insights: Ceribell, Inc. (CBLL) Q2 2025 MANAGEMENT VIEW * Xingjuan Chao, CEO, reported that total revenue for the second quarter of 2025 was $21.2 million, reflecting 38% growth over the same period last year, and highlighted…
SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today anno…
(Bloomberg) -- Medical-technology companies are helping revive initial public offerings in the life-sciences sector in the US after a tough year so far, during which regulatory uncertainty has hampered such activity. Most Read from Bloombe…
In October 2024, InvestingPro’s Fair Value model identified significant overvaluation in CeriBell, Inc. (NASDAQ:CBLL), a healthcare technology company specializing in seizure diagnostic solutions. The subsequent price movement has strongly…
Ceribell, Inc. (CBLL) President and CEO Chao Xingjuan, sold 25,000 shares of common stock on July 7, 2025, for a total of $442,500. The shares were sold at prices ranging from $17.02 to $18.7. The transaction comes as the stock, currently…